SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are sharply divided over a tokenized crypto asset claiming to represent SpaceX shares, with many warning it is a deceptive scheme unrelated to the company. While the community remains highly skeptical of these digital tokens, genuine excitement is building around the anticipated public listing of the space giant, sparking intense debate over valuations, sector competition, and the risks of falling for speculative pre-IPO hype.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

FARTCOIN is capturing significant community attention as traders debate its potential for a rebound and speculate on its relationship with other meme coins like $UPDOG. While some investors are actively buying the dip, discussion remains polarized between those anticipating a major breakout and others who are skeptical of the token's long-term sustainability.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability amid stagnant price action and anticipation surrounding the CLARITY Act's impact on crypto payment regulation. While some investors are aggressively accumulating tokens on the expectation of institutional adoption, others express deep frustration over the lack of transparency, declining market value, and the project's perceived inability to move in lockstep with the broader market.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention due to its focus on decentralized infrastructure, including sovereign cloud initiatives and AI-integrated applications that aim to bypass traditional tech giants. While some investors remain cautious about long-term price performance and market volatility, others are actively accumulating based on the project's ongoing technical developments and potential for real-world utility.

Tidal Trust III - VistaShares Electrification Supercycle ETF

VistaShares Electrification Supercycle® ETF

Investors are increasingly bullish on this electrification-focused ETF, viewing it as a strategic play on the rising demand for power infrastructure driven by the rapid expansion of AI and EV sectors. The community is highlighting the fund's potential to capture growth within the energy supply chain, often grouping it with other high-growth tech and infrastructure ETFs as a core portfolio holding.

Qorvo, Inc. provides semiconductor solutions for RF and power. The firm combines product and technology leadership, systems-level expertise, and global manufacturing scale to quickly solve its customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including consumer electronics, smart home/IoT, automotive, EVs, battery-powered appliances, network infrastructure, healthcare, and aerospace/defense. It operates through the following segments: High Performance Analog (HPA), Connectivity and Sensors Group (CSG), and Advanced Cellular Group (ACG). The HPA segment supplies RF and power management solutions for infrastructure, defense and aerospace, automotive power, and other markets. The CSG segment supplies connectivity and sensor components and systems featuring multiple technologies such as UWB, Matter, Bluetooth Low Energy, Zigbee, Thread, Wi-Fi, cellular IoT and MEMS-/BAW-based sensors. The ACG segment supplies cellular RF solutions for smartphones, wearables, laptops, tablets, and various other devices. The company was formed following the merger of RF Micro Devices, founded in 2015, and TriQuint Semiconductor, incorporated in 1981. It is headquartered in Greensboro, NC.

Qorvo Inc

Qorvo is trending following a series of analyst downgrades that highlight concerns over handset market saturation and the company's heavy reliance on smartphone demand. Market participants are actively debating the long-term impact of its pending merger with Skyworks and the potential for structural headwinds in the RF semiconductor sector.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is trending as the community debates its potential for a breakout, driven by its status as a high-TVL project on the Avalanche ecosystem and anticipation surrounding real-world asset (RWA) tokenization. While some investors are aggressively accumulating, citing attractive long-term metrics and a fully unlocked supply, others express frustration with recent price volatility and slow market movement.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is currently in focus as investors await clarity following a recent Complete Response Letter for its lead phosphate binder candidate, with the company actively coordinating with the FDA to resolve manufacturing deficiencies. Community discussion remains heavily centered on the upcoming July 14th virtual conference participation and the potential for a rapid regulatory re-submission path that could de-risk the investment thesis ahead of a commercial launch.

American Eagle Outfitters, Inc. is a multi-brand specialty retailer, which offers an assortment of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The firm operates stores in the United States, Canada, Mexico, Hong Kong, China and the United Kingdom. It also acquired two emerging brands to complement its existing brands, Tailgate, a vintage sports-inspired apparel brand, and Todd Snyder New York, a premium menswear brand. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters is trending as investors monitor a massive short interest of over 28 million shares while the stock experiences significant momentum driven by successful marketing campaigns featuring Sydney Sweeney and Travis Kelce. Community discussion is focused on the potential for a short squeeze alongside broader debates about the company's reliance on celebrity-driven retail sales versus macroeconomic pressures on the discretionary sector.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtual Protocol is currently a major focus for the AI agent sector, with the community closely tracking potential catalysts like Coinbase listings and broader integration within the Agentic AI narrative. While some traders are expressing frustration over price volatility, the conversation remains heavily centered on long-term accumulation and optimistic projections for the token's role in the expanding AI agent economy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Goldman Sachs said its Board of Directors increased the quarterly dividend to $4.50 per common share from $4.00 per common share</li><li>Goldman Sachs advised on some of the biggest deals of 2025. It advised in a $56.5 billion leverage buyout of Electronic Arts.</li><li>Company’s Investment banking fees came at $2.58 billion, 25% higher than the fourth quarter of 2024.</li></ul>Shares of Goldman Sachs rallied on Thursday after it posted higher profit for the fourth quarter (Q4) and raised dividend for its shareholders.&nbsp;Goldman Sachs reported a fourth quarter profit of $14.01 per share that surged past analyst estimates of $11.57 per share, as per data from Fiscal.ai.<h2 class="st-heading-2">M&amp;A Boost</h2>Major U.S. investment banks expect the rebound in mergers and acquisitions activity to continue in 2026, on the back of robust AI investment and tech deals.&nbsp;Goldman Sachs advised on some of the biggest deals of 2025. It advised in a $56.5 billion leverage buyout of Electronic Arts, as well as a $32 billion deal from Alphabet to acquire Wiz.Investment banking fees were $2.58 billion, 25% higher than the fourth quarter of 2024, primarily due to significantly higher net revenues in Advisory, reflecting a significant increase in completed mergers and acquisitions volumes, it said.&nbsp;<h2 class="st-heading-2">Dividend Rise</h2>Goldman Sachs said its Board of Directors increased the quarterly dividend to $4.50 per common share from $4.00 per common share, in a sign that the company expects a strong 2026.&nbsp;Goldman Sachs saw its expenses rise in 2025, primarily driven by investments in AI operations and higher compensation and bonuses to its executives. Its operating expense during the fourth quarter rose 18% to $9.72 billion.&nbsp;<h2 class="st-heading-2">Plans To Enter Booming Prediction Markets</h2>Goldman Sachs CEO, David Solomon told analysts in an earnings call that the company is looking to enter the prediction market.&nbsp;Solomon told analysts that he has met leaders of two major prediction market firms. Entry of a major Wall Street firm into this new and booming section of the financial world will give it the boost and more attention from investors as well as users.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GS trended in ‘extremely high’ territory amid ‘extremely high’ message volume.&nbsp;Shares of Goldman Sachs have risen 63% over the past 12 months.&nbsp; &nbsp;

David Solomon, Goldman Sachs CEO speaks during the Italian Tech Week 2025 at OGR Officina Grandi Riparazioni on October 3, 2025 in Turin, Italy.

Goldman Sachs Stock Rally After Upbeat Q4 Results, Increased Dividend

Goldman Sachs reported a fourth quarter profit of $14.01 per share that surged past analyst estimates of $11.67 per share, as per data from fiscal.ai.

Equity

Goldman Sachs reported a fourth quarter profit of $14.01 per share that surged past analyst estimates of $11.57 per share, as per data from fiscal.ai.


<ul class="summary-bullets"><li>Citi, Truist, and Stifel have maintained a “Buy” rating on the stock.</li><li>Citi analyst Atif Malik viewed Nvidia's licensing deal with Groq as a "clear positive.”</li><li>Truist said the reported $20 billion cost is high, but it is small relative to Nvidia's cash position and cash flow generation.</li></ul>Nvidia’s stock was in focus on Monday after several top brokerages voiced their confidence in the chipmaker’s $20 billion licensing deal with AI chip startup Groq, saying that it could extend its leadership in the AI infrastructure space.Analysts at Truist said that Nvidia's licensing agreement with Groq is intended to "fortify" its competitive positioning in inference versus tensor processing units, per TheFly. While the reported $20 billion cost is high, it is small relative to Nvidia's cash position and cash flow generation. The firm kept a “Buy” rating on the shares with a $275 price target.Meanwhile, Citi analyst Atif Malik viewed Nvidia's licensing deal with Groq as a "clear positive.” Citi believes Nvidia has navigated regulatory scrutiny, given that Groq will remain an independent company. It kept a “Buy” rating with a $270 price target.Stifel said that Nvidia's deal with Groq could extend AI infrastructure leadership and also kept a “Buy” rating on Nvidia with a $250 price target. UBS also remained bullish on Nvidia shares heading into 2026. It said that it expects appreciation from here to be driven almost by higher earnings estimates.<h2 class="st-heading-2">$20 Billion Groq Deal</h2>Last week, Groq said that it had entered into a non-exclusive licensing agreement with Nvidia for its inference technology. While the company did not disclose a price, CNBC reported the deal could be valued at $20 billion.As per the deal, Nvidia will onboard Groq’s senior management team, including founder Jonathan Ross and President Sunny Madra, to help advance and scale the licensed technology.The deal comes at a time when Nvidia is facing stiff competition in the AI inference space from firms like Advanced Micro Devices and Broadcom, among others. Groq specializes in fast AI inference, which will give Nvidia more breathing room on the leaderboard, as it already dominates the market for training AI models.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around NVDA stock trended in the ‘bearish’ territory amid “normal” message volume.&nbsp;<figure class="image"><img style="aspect-ratio:637/64;" src="https://news.stocktwits-cdn.com/nvidia_PNG_0fec69aa4e.webp" alt="On Stocktwits, retail sentiment around NVDA stock trended in the ‘bearish’ territory amid “normal” message volume. " width="637" height="64"></figure> Shares of Nvidia have gained 36% so far in 2025.&nbsp; &nbsp;

In this photo illustration, the Nvidia logo is seen in the background beside a printed circuit board (PCB). (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Analysts See Nvidia’s Groq Licensing Deal As A Clear Win For AI Leadership

Despite the reported $20 billion price tag, brokerages believe the deal is small relative to Nvidia's scale and long-term earnings power.

Nvidia’s Groq Tie-Up Draws Bullish Calls From Wall Street

<ul class="summary-bullets"><li>Hympavzi was approved by the U.S. Food and Drug Administration (FDA) in October 2024 for routine prophylaxis in adults and adolescents aged 12 years and older with severe hemophilia A or B without inhibitors.</li><li>The patient who died had hemophilia A and inhibitors.</li><li>Pfizer is now actively gathering information to understand the circumstances surrounding the death and identify the cause.</li></ul>One of the patients enrolled in Pfizer’s trial of Hympavzi in people living with a bleeding disorder died earlier this month, the company said.The company said in a letter to the World Federation of Hemophilia (WFH) and National Bleeding Disorders Foundation (NBDF) that the patient suffered a fatal thrombotic stroke after a minor surgery on December 14.Hympavzi was approved by the U.S. Food and Drug Administration (FDA) in October 2024 for routine prophylaxis in adults and adolescents aged 12 years and older with severe hemophilia A or B without inhibitors. Pfizer is now studying Hympavzi in people living with hemophilia A or B irrespective of whether they have inhibitors.Hemophilia A and B are bleeding disorders, but some patients develop "inhibitors" that stop standard blood clotting factors replacement therapy from working, making bleeds harder to stop. The patient who died had hemophilia A and inhibitors.The patient participated in the active treatment phase of the parent study in 2022 prior to entering the long-term extension study in 2023, according to Pfizer.<h2 class="st-heading-2">Pfizer’s Next Moves</h2>Pfizer is now actively gathering information to understand the circumstances surrounding the death and identify the cause with the support of the trial investigator and an independent external Data Monitoring Committee. The drugmaker said that regulatory authorities and investigators have been informed.The World Federation of Hemophilia (WFH) and National Bleeding Disorders Foundation (NBDF) &nbsp;noted that thrombosis is an adverse event of special interest with Hympavzi due to the drug’s mechanism of action as a rebalancing agent that targets tissue factor pathway inhibitor (TFPI) to increase thrombin generation for clot formation.“The use of marstacimab (Hympavzi) should include close monitoring for symptoms of thrombosis and other adverse events, especially in surgical settings in combination with clotting factor concentrates or bypassing agents,” they <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://wfh.org/article/wfh-and-nbdf-statement-on-severe-adverse-event-with-marstacimab-rebalancing-agent-for-hemophilia/">said</a> in a statement.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PFE fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours while message volume fell from ‘extremely high’ to ‘normal’ levels.A Stocktwits user expressed disappointment over the stock trading in the red while major pharma stocks rallied.<stembedurl>https://www.stocktwits.com/Micheal_Pothead/message/639969189</stembedurl> <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> has dropped nearly 6% this year and by over 6% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">FJET Stock Takes A Breather Post Massive Rally – Starfighters Space Releases 2026 Plans After Stock Market Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study

The company said in a letter to the World Federation of Hemophilia (WFH) and National Bleeding Disorders Foundation (NBDF) that the patient suffered a fatal thrombotic stroke after a minor surgery on December 14. 

<ul class="summary-bullets"><li>Pfizer provides Covid vaccine called Comirnaty in addition to an antiviral medication used to treat COVID-19 called Paxlovid.</li><li>In 2026, the company expects the revenue to fall further or stay at 2025 levels within the range of $59.5 to $62.5 billion, owing to Covid product sales falling further to about $5 billion.</li><li>The company now expects earnings per share of about $3 to $3.15 for the current financial year and expects it to fall further down to $2.8-$3 in the financial year 2026.</li></ul>Pfizer shares fell about 5% on Tuesday, on pace for their worst session in over eight months, after BofA lowered its price target following the company’s updated guidance on waning Covid-19 product demand.The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion. Revenue from the company’s Covid-19 products is expected to be $6.5 billion. &nbsp;Pfizer provides Covid vaccine called Comirnaty in addition to an antiviral medication used to treat COVID-19 called Paxlovid. In the third quarter, Paxlovid and Comirnaty saw revenues in the quarter down by 55% and 19%, respectively, on a total basis as Covid-19 infections continue to drop.<h2 class="st-heading-2">Analyst Take</h2>BofA analyst Jason Gerberry subsequently lowered its price target on Pfizer to $27 from $28 while retaining a ‘Neutral’ rating on the shares. The analyst highlighted that the company is now looking to progress its obesity pipeline as Covid product demand falters.Pfizer <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-sees-metsera-drugs-hit-market-as-early-as-2028-after-completing-acquisition-report/cLP9fAwREE9">acquired</a> obesity drugmaker Metsera for up to $86.25 per share in November after a bidding war with Danish drugmaker Novo Nordisk. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year, citing risks of liver enzyme elevations, leaving it with no in-house obesity drug candidate. The company expects Metsera’s MET-097i, a monthly injectable GLP-1, to be market-leading. The experimental drug is about to begin late-stage development.“Following the recent closing of our Metsera acquisition, our new exclusive global collaboration and license agreement with Yao Pharma and other Pfizer programs that include our GIPR antagonist candidate, we have a robust and diverse obesity portfolio,” CEO Albert Bourla said on Tuesday. “We plan to move quickly in 2026 to advance about 15 programs with many of them being phase 3 studies just for this program.”<h2 class="st-heading-2">Looking Further Ahead</h2>In 2026, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides">expects</a> the revenue to fall further or stay at 2025 levels within the range of $59.5 to $62.5 billion, owing to Covid product sales falling further to about $5 billion and loss of exclusivity on certain products creating a negative impact of about $1.5 billion. Wall Street, on average, expects FY26 revenue of about $61.68 billion, to the top end of current guidance range.The company now expects earnings per share of about $3 to $3.15 for the current financial year and expects it to fall further down to $2.8-$3 in financial year 2026, below an analyst estimate of $3.06. Pfizer’s recent acquisition of Metsera is further expected to increase research and development expenses to $10.5-$11.5 billion from $10 to $11 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PFE rose from ‘bearish’ &nbsp;to ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the new update from the company highlighting that the downside is minimal.<stembedurl>https://www.stocktwits.com/jjflanders/message/639319453</stembedurl>Yet another called for a CEO replacement.<stembedurl>https://www.stocktwits.com/PFElinepfrenzy1990/message/639309007</stembedurl><a href="https://stocktwits.com/symbol/PFE">PFE stock</a> fell 5% this year and by 1% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-aldeyra-therapeutics-stock-surging-after-fda-delayed-its-dry-eye-drug-decision/cLeJL0aREpd">Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Pfizer Stock On-Track For Worst Day In Over 8 Months As BofA Flags Faster Covid-19 Product Erosion

The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion.

Evercore ISI analysts reportedly expect the fire at a New York aluminum plant will erode up to $1 billion from Ford Motor Co.’s (F) earnings.According to a Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/autos-transportation/fire-aluminum-plant-hit-fords-bottom-line-by-up-1-billion-analyst-says-2025-10-08/">report</a>, Ford refused to comment on Evercore’s estimates. However, it told the news agency that it has been working closely with Novelis and exploring all possible alternatives to minimize potential disruptions.A large portion of Novelis’ Oswego, New York, aluminum plant was knocked offline until early next year after a September 16 blaze destroyed its hot mill. This section produces aluminum for vehicles. Ford, the plant’s biggest customer, relies heavily on Oswego material for the aluminum-bodied F-150, its most profitable model.The automaker is reportedly expected to disclose the effects of the outage in its earnings report later this month. Shares of the company traded 1% lower at the time of writing.Ford’s stock witnessed a near 178% rise in retail user message count over the past 24 hours, as of Wednesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/F">F stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Novelis, a unit of India’s Hindalco Industries, produces over 350,000 metric tons of aluminum annually for automakers such as Ford, Toyota, Hyundai, Volkswagen, and Stellantis. According to Evercore analysts, while other automakers will also be affected by the fire, Ford will see the biggest hit of $500 million to $1 billion to its earnings before interest and taxes.The F-series is Ford’s best-selling vehicle and truck. In the second quarter (Q2), the company sold 207,732 units of the truck in the U.S. In fact, the company has sold over 600,000 units of the truck year-to-date in the U.S., outpacing its nearest competitor by an estimated 170,000 units.Ford stock is up 19% this year and approximately 13% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/archer-aviation-cleveland-clinic-abu-dhabi-to-launch-uae-first-hospital-based-vertiport/ch6EjGLR3iK">Archer Aviation, Cleveland Clinic Abu Dhabi To Launch UAE’s First Hospital-Based Vertiport</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford Explorer electric cars are parked on car transporters on the Ford factory premises. (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Ford Faces Up To $1 Billion Hit After New York Aluminum Plant Fire, Analysts Reportedly Say

According to a Reuters report, Ford refused to comment on Evercore’s estimates.

Shares of Ford Motor Co. (F) slipped 6% on Tuesday morning following reports of a late-night fire at Novelis’ Oswego, New York, aluminum plant.According to a <a href="https://stocktwits.com/news-articles/markets/equity/ford-f-150-faces-fresh-setback-after-blaze-knocks-out-key-aluminum-supplier-in-new-york/ch62H32R3gy">report</a> by The Wall Street Journal, a large portion of the Oswego plant was knocked offline until early next year after a September 16 blaze destroyed its hot mill. This section produces aluminum for vehicles. Ford, the plant’s biggest customer, relies heavily on Oswego material for the aluminum-bodied F-150, its most profitable model.Ford said it sources aluminum from multiple suppliers and has been working closely with Novelis since the fire. “A full team is dedicated to addressing the situation and exploring all possible alternatives to minimize any potential disruptions,” the company said in a statement to The WSJ.The automaker is reportedly expected to disclose the effects of the outage in its earnings report later this month.<a href="https://stocktwits.com/symbol/F">Ford shares</a> witnessed a 166% rise in retail user message count over the past 24 hours, as of Tuesday morning. On Stocktwits, retail sentiment around F stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_10_13_47_AM_png_84f820d67c.webp" alt="F's Sentiment Meter and Message Volume as of 10:14 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1366" height="126"><figcaption>F's Sentiment Meter and Message Volume as of 10:14 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the stock dip as “short-lived.”<stembedurl>https://stocktwits.com/tradinwarrior/message/631307635</stembedurl>A more pessimistic user, however, opined that the shares will fall more “little by little.”<stembedurl>https://stocktwits.com/Akisawada/message/631303479</stembedurl>Novelis, a unit of India’s Hindalco Industries, produces over 350,000 metric tons of aluminum annually for automakers such as Ford, Toyota, Hyundai, Volkswagen, and Stellantis. The company said it’s reallocating some production to its European, Brazilian, and South Korean plants, though high U.S. import tariffs could increase costs.Meanwhile, the F-series is Ford’s <a href="https://stocktwits.com/news-articles/markets/equity/ford-us-sales-soar-8.2-percent-in-q3-over-strong-truck-suv-demand/chCY42ZR3a8">best-selling vehicle</a> and truck. In the second quarter, the company sold 207,732 units of the truck in the U.S. In fact, the company has sold over 600,000 units of the truck year-to-date in the U.S., outpacing its nearest competitor by an estimated 170,000 units.Ford stock is up 20% this year and approximately 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lexeo-therapeutics-stock-rallies-on-discussions-with-fda-to-expedite-friedreich-ataxia-drug-approval-process/ch6PXccR3h7">Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Ford F-150 Lariat PowerBoost ybrid pickup truck is displayed for sale at a Ford dealership on August 21, 2024 in Glendale, California. (Photo by Mario Tama/Getty Images)

Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’

The automaker is reportedly expected to disclose the effects of the outage in its earnings report later this month.

Ford Motor Co. (F) on Wednesday announced that it sold 545,522 vehicles in the U.S. in the third quarter (Q3), marking a growth of 8.2% from the corresponding quarter of 2024.The growth was spurred by an increase in sales of the company’s trucks and SUVs by 7.4% and 9.7%, respectively. The F-series continued to be the company’s best-selling vehicle and truck in the quarter, with 207,732 units sold. In fact, the company has sold over 600,000 units of the truck year-to-date, outpacing its nearest competitor by an estimated 170,000 units.Ford’s EV sales, meanwhile, rose 30.2% to 30,612 units as customers rushed to make their purchases before the federal tax credit on EVs expired on September 30. Internal combustion engine vehicles, however, accounted for a whopping 84% of the company’s overall sales.<a href="https://stocktwits.com/symbol/F">Ford shares</a> traded 2% higher at the time of writing. On Stocktwits, retail sentiment around Ford stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Among SUVs, the Ford Bronco was the company’s best-selling vehicle in the quarter, with sales rising 41.3% to 37,858 units. The Lincoln brand contributed 23,760 units to the company’s overall sales in the quarter, representing a 7.6% year-over-year decline.Among the company’s three electric vehicles, the Mustang Mach-E SUV was the best-seller, with 20,177 units sold. The company also sold 10,005 units of its electric truck, the F-150 Lightning.“This quarter's growth showcases our portfolio's unmatched flexibility and breadth,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s205.q4cdn.com/882619693/files/doc_news/2025/Oct/01/Ford-U-S-Q3-2025-Sales-Release.pdf">said</a> Ford executive Andrew Frick. The company is now looking forward to starting shipping the recently revealed Explorer Tremor and F-150 Lobo street truck in the fourth quarter.F stock is up 23% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fortress-biotech-stock-falls-pre-market-after-fda-refuses-to-approve-drug-for-treating-menkes-disease/chCYd94R3aj">Why Is Fortress Biotech Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford US Sales Soar 8.2% In Q3 Over Strong Truck, SUV Demand

Ford’s EV sales, meanwhile, rose 30.2% to 30,612 units as customers rushed to make their purchases before the federal tax credit on EVs expired on September 30.

Ford Motor Co. (F) CEO Jim Farley reportedly believes that the elimination of federal tax credit on the purchase of electric vehicles and other Trump policies will sharply curtail EV demand in the U.S.Farley predicted the share of zero-emission vehicles could decline by half, according to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/ford-s-ceo-sees-trump-policies-cutting-us-ev-market-in-half?srnd=homepage-americas">report</a>. ZEVs currently account for 10% of the domestic market.&nbsp;“I wouldn’t be surprised if EV sales in the U.S. go down to 5%,” Farley said at a conference in Detroit, as reported by Bloomberg. The CEO, however, said the company is looking to add hybrid production to its battery and EV plants, the report noted.<a href="https://stocktwits.com/symbol/F">Ford shares</a> traded 1% lower on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around the stock stayed within the ‘bullish’ territory, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_2_06_42_PM_png_de870fd3da.webp" alt="F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>In the second quarter, Ford’s EV segment, known as Model e, saw its operating loss widen to $1.3 billion, pressured by tariffs and ramp-up costs at its new battery plant in Marshall, Michigan.Ford’s current EV lineup in the U.S. is comprised of just three vehicles: the F-150 Lightning pickup truck, the Mustang Mach-E SUV, and the E-Transit van. This year, through the end of August, the company sold a cumulative 57,888 units of the three models, marking a drop of about 6% from the corresponding period last year, despite a 5.5% increase in internal combustion engine vehicles.Ford stated last month that it plans to introduce a new group of affordable electric vehicles starting in 2027 to expand its EV lineup. The first in line would be a midsize pickup truck assembled at Ford’s Louisville Assembly Plant with an expected starting price of $30,000, the company added.F stock is up by about 21% this year and by about 13% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moonlake-immunotherapeutics-stock-draws-wall-street-attention-post-mondays-plunge/chDDKdWR39j">MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford Motor Company CEO Jim Farley speaks at a Ford Pro Accelerate event on September 30, 2025 in Detroit, Michigan. (Photo by Bill Pugliano/Getty Images)

Ford CEO Jim Farley Reportedly Expects US EV Demand To Decline Sharply – Here’s Why

According to a Bloomberg report, Farley predicted the share of zero-emission vehicles could fall by half. 

Ford Motor Co. (F) is recalling 115,539 vehicles in the U.S. over concerns regarding loss of steering control, the National Highway Traffic Safety Administration (NHTSA) said on Wednesday.The recall includes certain model year 2020-2021 F-250, F-350, and F-450 trucks. <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V626-1284.pdf">According</a> to the regulator, the steering column’s upper shaft may detach from the column, resulting in a loss of steering control and an increased risk of a crash.As for a solution, dealers will inspect the steering column and repair or replace the upper shaft as necessary, it said. The customer will not be charged for the fix. The final remedy is expected to be available by December 2025, the regulator addedFord shares rose 0.3% on Wednesday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/F">Ford</a> remained within the ‘bearish’ territory, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_10_09_13_AM_png_3dd461500b.webp" alt="F's Sentiment Meter and Message Volume as of 10:09 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>F's Sentiment Meter and Message Volume as of 10:09 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>According to the NHTSA filing, Ford’s team reviewed supplier process and maintenance records to determine the recall population. The vehicles affected by the recall were built between Feb. 19, 2019, and Sept. 30, 2020, at the Kentucky Truck Plant.The regulator stated that Ford is aware of seven warranty claims, three field reports, and four customer call hotline reports, all of which are likely related to the concerns as of September 11. However, the company is not aware of any accidents or injuries related to the condition, it added.Ford stock is up approximately 19% this year and over 8% in the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford logo seen on a car outside a Ford dealership in Edmonton, AB, Canada, on February 02, 2025. (Photo by Artur Widak/NurPhoto via Getty Images)

Ford Recalls Over 115,000 F-Series Trucks Due To Loss Of Steering Control Concerns

According to NHTSA, the steering column’s upper shaft may detach from the column, resulting in a loss of steering control and an increased risk of a crash. 

Bristol Myers Squibb (BMY) announced on Tuesday that a late-stage study evaluating Iberdomide in patients with relapsed or refractory multiple myeloma demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm, when combined with standard therapies.Minimal residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body after treatment. MRD assessment has emerged as a highly sensitive and clinically meaningful tool for evaluating treatment response in multiple myeloma, a cancer of plasma cells in the bone marrow that leads to tumors in multiple bones, the company said.While MRD negativity does not necessarily mean all cancer cells are gone, it may predict improved clinical outcomes, including longer remission and survival, it added.The trial will now continue without changes to evaluate the progression-free survival (PFS), overall survival, and safety endpoints, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Phase-3-EXCALIBER-RRMM-Study-Evaluating-Iberdomide-in-Combination-with-Standard-Therapies-Demonstrated-a-Significant-Improvement-in-Minimal-Residual-Disease-Negativity-Rates-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx">said</a>. Bristol Myers noted that it plans to discuss the results with health authorities.Shares of BMY traded marginally higher at the time of writing. On Stocktwits, retail sentiment surrounding <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> remained within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:581/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_12_52_19_PM_png_34f256a597.webp" alt="BMY's Sentiment Meter and Message Volume as of 12:05 p.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="581" height="60"><figcaption>BMY's Sentiment Meter and Message Volume as of 12:05 p.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Earlier this month, BioNTech SE (BNTX) and Bristol Myers Squibb also presented interim data from a global randomized mid-stage trial evaluating their drug Pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer. The data showed encouraging anti-tumor responses, with a positive trend in progression-free survival, or the length of time a patient with a disease lives without it worsening.According to Koyfin data, 19 out of 26 analysts covering Bristol-Myers stock rate it a ‘Hold’, six rate it ‘Buy’ or higher, while one rates it a ‘Sell.’ The average price target on the stock is $52, representing an upside of over 17% from current price levels.BMY stock is down by about 20% this year and by about 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-says-updated-mnexspike-covid-shot-demonstrated-rbust-immune-response-in-study/chDhMlcR35J">Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study

The company announced that the trial will proceed without changes to evaluate the progression-free survival, overall survival, and safety endpoints.

IOO
iShares Global 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest IOO News

IOOiShares Global 100 ETF